GB2361535A - Polymorphisms in the 5'leader cistron of the beta2-adrenergic receptor - Google Patents

Polymorphisms in the 5'leader cistron of the beta2-adrenergic receptor

Info

Publication number
GB2361535A
GB2361535A GB0115239A GB0115239A GB2361535A GB 2361535 A GB2361535 A GB 2361535A GB 0115239 A GB0115239 A GB 0115239A GB 0115239 A GB0115239 A GB 0115239A GB 2361535 A GB2361535 A GB 2361535A
Authority
GB
United Kingdom
Prior art keywords
adrenergic receptor
disclosed
polymorphisms
beta2
cistron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0115239A
Other versions
GB0115239D0 (en
GB2361535B (en
GB2361535A8 (en
Inventor
Stephen B Ligget
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of GB0115239D0 publication Critical patent/GB0115239D0/en
Publication of GB2361535A publication Critical patent/GB2361535A/en
Publication of GB2361535A8 publication Critical patent/GB2361535A8/en
Application granted granted Critical
Publication of GB2361535B publication Critical patent/GB2361535B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A novel polymorphic site in the 5' leader cistron of the …<SB>2</SB>-adrenergic receptor (…<SB>2</SB>AR) gene is disclosed. The polymorphisms present at this site result in different levels of inhibition of translation of …<SB>2</SB>AR mRNA. Compositions and methods for genotyping this polymorphic site are disclosed. In addition, methods for using this genotype information are disclosed, including predicting genetic predisposition to a disease modified by …<SB>2</SB>AR expression and predicting a patient's bronchodilating response to …2-agonists.
GB0115239A 1998-11-25 1999-11-24 Polymorphisms in the 5'leader cistron of the beta 2 - adrenergic receptor Expired - Fee Related GB2361535B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10988698P 1998-11-25 1998-11-25
PCT/US1999/027963 WO2000031307A1 (en) 1998-11-25 1999-11-24 POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE β2-ADRENERGIC RECEPTOR

Publications (4)

Publication Number Publication Date
GB0115239D0 GB0115239D0 (en) 2001-08-15
GB2361535A true GB2361535A (en) 2001-10-24
GB2361535A8 GB2361535A8 (en) 2001-11-08
GB2361535B GB2361535B (en) 2004-02-25

Family

ID=22330094

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0115239A Expired - Fee Related GB2361535B (en) 1998-11-25 1999-11-24 Polymorphisms in the 5'leader cistron of the beta 2 - adrenergic receptor

Country Status (3)

Country Link
AU (1) AU1744500A (en)
GB (1) GB2361535B (en)
WO (1) WO2000031307A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797472B1 (en) 1999-03-12 2004-09-28 Genaissance Pharmaceuticals, Inc. Variation in drug response related to polymorphisms in β2-adrenergic receptor
US6586183B2 (en) 2000-04-13 2003-07-01 Genaissance Pharmaceuticals, Inc. Association of β2-adrenergic receptor haplotypes with drug response
AU2001255448A1 (en) 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
WO2006031955A2 (en) 2004-09-14 2006-03-23 The Regents Of The University Of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5573910A (en) * 1993-02-12 1996-11-12 Board Of Regents, The University Of Texas System Detection of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients involving the algu gene
US5589331A (en) * 1992-04-24 1996-12-31 The United States Of America As Represented By The Department Of Health And Human Services Method for detecting abnormal serotonergic function
WO1997035973A2 (en) * 1996-03-26 1997-10-02 Vetigen SEQUENCES CODING FOR CANINE β2- AND β3-ADRENERGIC RECEPTORS AND APPLICATIONS THEREOF AS PROBES AND FOR THE EXPRESSION OF PEPTIDES
US5700907A (en) * 1991-02-12 1997-12-23 Roussel Uclaf Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5817477A (en) * 1995-06-06 1998-10-06 Human Genome Sciences, Inc. Adrenergic receptor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700907A (en) * 1991-02-12 1997-12-23 Roussel Uclaf Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5589331A (en) * 1992-04-24 1996-12-31 The United States Of America As Represented By The Department Of Health And Human Services Method for detecting abnormal serotonergic function
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5573910A (en) * 1993-02-12 1996-11-12 Board Of Regents, The University Of Texas System Detection of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients involving the algu gene
US5817477A (en) * 1995-06-06 1998-10-06 Human Genome Sciences, Inc. Adrenergic receptor
WO1997035973A2 (en) * 1996-03-26 1997-10-02 Vetigen SEQUENCES CODING FOR CANINE β2- AND β3-ADRENERGIC RECEPTORS AND APPLICATIONS THEREOF AS PROBES AND FOR THE EXPRESSION OF PEPTIDES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Amer. J. of Resp. Crit. Care Med. 1997, 156, pp.S156-S162 - Liggett *
J. of Clin. Investigation 1995, 95, pp.1635-1641 - Turki et al. *
Proc. Natl. Acad. Sci. USA 1996, 93, pp.10483-10488 - Turki et al. *

Also Published As

Publication number Publication date
GB0115239D0 (en) 2001-08-15
GB2361535B (en) 2004-02-25
WO2000031307A1 (en) 2000-06-02
AU1744500A (en) 2000-06-13
GB2361535A8 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
Vingsbo-Lundberg et al. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats
Price et al. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation
Ferguson et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
Yoshikawa et al. Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21. 1-p21. 2
DE69800415D1 (en) PROSTATE CANCER GENE
US6800436B1 (en) Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in LKB1 gene
US6448003B1 (en) Genotyping the human phenol sulfotransferbase 2 gene STP2
GB2361535A (en) Polymorphisms in the 5&#39;leader cistron of the beta2-adrenergic receptor
US6492115B1 (en) Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
Britten et al. Genetic delineation of management units for the desert tortoise, Gopherus agassizii, in northeastern Mojave Desert
WO2002016643A3 (en) Dna pooling methods for quantitative traits using unrelated populations or sib pairs
Casasnovas et al. Clinical and molecular analysis of X‐linked Charcot‐Marie‐Tooth disease type 1 in Spanish population
Nonneman et al. Comparative mapping of a region on chromosome 10 containing QTL for reproduction in swine 1
Walkey et al. Characterization of the murine phosphatidylethanolamine N-methyltransferase-2 gene
Tasheva et al. Assignment [sup 1] of mimecan gene (OGN) to human chromosome band 9q22 by in situ hybridization.
Klöting et al. Triplet repeat in the Repin1 3′‐untranslated region on rat chromosome 4 correlates with facets of the metabolic syndrome
Klootwijk et al. Further characterization of the genetic defect of the Bent tail mouse, a mouse model for human neural tube defects
Tolwani et al. Structure and chromosomal location of the mouse medium-chain acyl-CoA dehydrogenase-encoding gene and its promoter
IAKOUBOVA et al. Microsatellite marker panels for use in high-throughput genotyping of mouse crosses
WO2002006294A3 (en) Haplotypes of the mmp13 gene
Williams‐Blangero et al. Genetic management of nonhuman primates
Sander et al. Exploration of a putative susceptibility locus for idiopathic generalized epilepsy on chromosome 8p12
Sander et al. No evidence for a susceptibility locus for idiopathic generalized epilepsy on chromosome 18q21. 1
WO2003066903A3 (en) Genetic markers for bone mass
Kratzsch et al. Congenital progressive ataxia and spastic paresis, a hereditary disease in swine, maps to Chromosome 3 by linkage analysis

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20051124